𝛼SK or Searchbullish
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions
On June 8, 2026, MetaVia, Inc. (MTVA) announced the presentation of new late-breaking data for DA-1726, the company's oxyntomodulin analog...
What is covered in the Full Insight:
- Introduction
- Business Update
- Key Data from ADA 2026
- Phase 1 Clinical Trial Details
- Conclusion
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions18 Jun 2026
x